Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.43 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.42 |
| ▸ | PLA2G4A | P47712 | 4/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4606613 | 0.90 | HTR6 (0.46) | HTR6PPARGPPARDPPARAPTGER4 | |
| SCHEMBL4606521 | 0.90 | PPARG (0.40) | HTR6PPARGPPARDPPARAPTGER4 | |
| SCHEMBL4606270 | 0.90 | LTB4R (0.52) | HTR6PPARGPPARDPPARAPTGER4 | |
| SCHEMBL4604332 | 0.89 | PPARG (0.49) | HTR6PPARGPPARDPPARAPLA2G4A | |
| SCHEMBL4605289 | 0.88 | PPARG (0.47) | HTR6PPARGPPARDPPARAPLA2G4A | |
| SCHEMBL4618320 | 0.85 | PPARG (0.45) | HTR6PPARGPPARDPPARAFFAR1 | |
| SCHEMBL4605383 | 0.85 | PPARG (0.44) | HTR6PPARGPPARDPPARAPLA2G4A | |
| SCHEMBL4606105 | 0.84 | PPARG (0.52) | HTR6PPARGPPARDPPARALTB4R | |
| SCHEMBL4605982 | 0.84 | PPARG (0.63) | HTR6PPARGPPARDPPARA | |
| SCHEMBL4606060 | 0.84 | PPARG (0.46) | HTR6PPARGPPARDPPARAPLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943245-A2 | 1,3-DISUBSTITUTED INDOLE DERIVATIVES FOR USE AS PPAR MODULATORS | PLEXXIKON, INC. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20070072904-A1 | 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders | PLEXXIKON INC | 2007-03-29 | — | — | US | disclosed |
| US-20070072904-A1 | 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders | PLEXXIKON INC | 2007-03-29 | — | — | US | disclosed |
| US-20070072904-A1 | 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders | PLEXXIKON INC | 2007-03-29 | — | — | US | disclosed |
| WO-2007030559-A2 | 1, 3-DISUBSTITUTED INDOLE DERIVATIVES FOR USE AS PPAR MODULATORS | PLEXXIKON, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072904-A1 | 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders | PPARG, PPARA, PPARD | HTR6 178/4885PPARG 1/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.